dendritic cell vaccine therapy + fludeoxyglucose F 18 + laboratory biomarker analysis + NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL + positron emission tomography + FLUDARABINE PHOSPHATE + Cyclophosphamide + ALDESLEUKIN for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Oct 2012: Trial registered, NCT01697527
  2. 2 Nov 2012: Trial started, NCT01697527

The trials

NCT01697527: Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

State
Under way
Phase
Phase 2
People
6 taking part
Started
2 Nov 2012
Primary completion
2 Nov 2026
Arms
Treatment (gene and vaccine therapy)
Results
None posted
  1. 2 Oct 2012: Trial registered
  2. 2 Nov 2012: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.